Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the # of interest to us here is:
Seroquel - weekly TRX DOLLARS MALLINCRODT: 533.87K 10/13/2017 - 526K 10/06/2017
What we need also is Seroquel XR - WEEKLY TRX COUNT MALLINCRODT: for 10/13... should be a number around 700-800???
and September Seroquel - MONTHLY TRX DOLLARS MALLINCRODT: for September ... should be a number around $1.856 million
When you have time.
They are talking about in human proof of concept - therefore I assume the oxycodone product they are testing it with would have to be FDA approved... no???
I don't know fabius... there is so much that doesn't make sense to me... even my supposition that PODRAS is being applied to OxyContin may be wishful thinking because if it's Purdue that bought the offering - why would they also get warrants???
But, it's still in back of my mind that the Purdue CEO in 2016 said they may buy a platform... yet nothing has been bought... and it felt to me he might have been alluding to PODRAS.
Maybe I'm just trying to ease the pain of feeling stuck... and hoping that I will some day SOON be made whole.
Then again... why not disclose what product they are applying it to???
Excellent post... all based on astute observations... and indicate most likely conclusions.
My Ameritrade Think or Swim says earnings are Thursday Oct 12th AFTER HOURS ... but I don't think that is anything other than info derived from last years ER.
With change in CFO --- who knows
NJ stocks 14 inch to 22 inch trout on Thursday... and I'm going fishing... would be nice to come home to a good report
Seroquel + Focalin Sales to 9/29/17
Note that FACTUAL Sept 2017 year to date Sales of $57.25 million was used to derive assumed Jan and Feb sales #s.
2nd quarter Sales for Focalin were $20.41 million - from that and 2nd Qtr royalty payments we can get a very good estimation of Royalty %age for Focalin... and can get a very good estimate on Focalin's 3rd Qtr royalty payments... now who has the exact 2nd qtr payment on Focalin??? If it was $2 million??? then 10% royalty on 3rd Qtr Focalin Royalties will be $1.763 million.
Looking forward to figuring out Seroquel's Royalties next Earnings Report.
Seroquel Sales to Sept. 29th, 2017
Note that sales from Sept 2nd to Sept 29th add up to $1,732.80... add to that 2/28ths of that amount, or $123.76 for the additional 2 days in September and you have Total September Sales estimated at $1,856.56... that is an estimate but should prove to be right on.
You know... I have no idea what the hell happened today.
Did a fund or heavy trader/investor interpret the Cigna news as being a positive thing for IPCI's rexista down the road and take a position???... one trade was a 150K share block.
Or, perhaps market makers saw that shorts had buy-to-cover positions set up at $1.2X so they took it up there, sold a bunch and headed back down???
Trying to figure out what happens in trading is like standing on the edge of a lake and trying to figure out... also known as "guessing"... where the fish are.
Yes... I know what you mean... just wanted someone else to say it.
I simply can't imagine that they would not want to buy some - re-phrase that... that they would not want to buy a shit load down here... if it were possible/legal for them to do so.
Can you share your thoughts on what might have caused the change in motion??? by Purdue the day after the ADCOM fiasco???
Can't help but wonder why the Odidis have not bought some IPCI stock at $1 a share on the open market... that in itself would be a boost of confidence... hard to believe they are constantly under negotiatios, thereby making it illegal to buy.
All the options ~ 5 million they own are at $3+ a share... you would think he would see getting some at $1.00 would be a bargain.
https://www.amazon.com/Licensing-Royalty-Rates-Gregory-Battersby/dp/1454811803/ref=sr_1_fkmr0_1?s=books&ie=UTF8&qid=1506889712&sr=1-1-fkmr0&keywords=The+Royalty+Rate+Report+2012
having your own FULL copy - $222.00
Reporting your findings here - priceless
LOL
The Royalty Rate Report 2012
Royalty Rate Deals Chart: 2004 – January 2012 - see page 150
Table A.1, on the pages following this introductory section, charts royalty- revealing deals since January 2004, sourced from the PharmaDeals® v4 Agreements database. The chart is an updated version of a spreadsheet previously available as part of a report published by PharmaDeals in 2008.
Care should be taken in any interpretation of declared royalty rates. The declared royalty is generally given as a percentage of net sales. However, this is not always the case. Figures of 50% may relate to a particularly high percentage of sales in, for example, a distribution deal for a late-stage or launched product but, occasionally, they relate to a royalty derived from a 50:50 split of pro?t as in a joint venture.
http://files.pharmadeals.net/contents/toc_rrr2012.pdf
Wealth of information... if only they posted the whole document rather than pieces here and there.
I'm not big on reading through big volumes like this - maybe someone more apt - like numbersarefun - can go through it... although incomplete... and pull out some info that can shed some light on IPCI's contract structure.
OK - I was guessing but was guessing right...
http://www.gilead.com/news/press-releases/2009/3/gilead-sciences-agrees-to-acquire-cv-therapeutics-for-2000-per-share
Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
Happened March 12, 2009
Seroquel XL Sales Chart - Actual to Sept 22, 2017
Hopefully The 13.19% growth for that week steers us back on track to an estimate total of $1.9 million for the month of September, which alone, is more than the 2nd quarter total.
I've added a Quarterly column to the chart for Quarter to Quarter comparison.
An 8% average weekly growth rate in October and a 6% average weekly growth rate in November will put us on track to make the $7.671 million 3rd Quarter estimate a reality.
Next Friday we will have Actual Sales for the week of September 29th, and hopefully also the Actual Month of September sales.
-SeroquelXR® accepted by the FDA on May 3rd, 2011
-Seroquel/AstraZeneca patent litigation settlement reached on July 31st, 2012
-Seroquel currently at the 44 month mark from the patent infringement settlement date awaiting FDA approval
-AZ's patent protection on SeroquelXR expires in November 2016 so this particular ANDA approval can in fact be telegraphed...
as IPCI should receive tentative FDA approval prior to November 2016 and have SeroquelXR full commercialized in May 2017
as soon as Handa's 180 days exclusivity expires
-SeroquelXR® is an oral psychotropic agent indicated for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
According to Source Healthcare Analytics, sales of Seroquel XR® in the United States were approximately
$1.1 billion (TRx MBS Dollars) for the 12 months ended February 2013.
Speculation is strong that the ANDA partnership deal announced with TEVA was on SeroquelXR® but both IPCI & TEVA
have yet to disclose on which ANDA it is.
On Sept 2012 IPCI filed ANDAS for both Keppra and Pristiq... the FDA accepted the Keppra filing... which has already been approved but requested a re-do on one of the 3 bioequivalence studies for Pristiq.
https://www.thestreet.com/story/11869049/1/intellipharmaceutics-announces-update-on-its-generic-versions-of-keppra-xrr-and-pristiqr.html
Wait... that's logic!!!... is logic allowed here now???
Are we allowing logic now???... or is he cheating???
Buon Giorno fabius